Pfizer Inc. (PFE)

Check out top investors' recommendation for PFE
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
48.29
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care physicians for Alzheimer’s disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation therapeutic and disease areas. The company's Specialty Care and Oncology segment provides human prescription pharmaceutical products primarily prescribed by physicians for therapeutic and disease areas, such as anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines. This segment also offers human prescription pharmaceutical products addressing oncology and oncology-related illnesses. Its Established Products and Emerging Markets segment offers human prescription pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions, as well as that are sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. The company's Animal Health segment offers products and services to prevent and treat disease in livestock and companion animals, including anti-infectives, vaccines, parasiticides, medicinal feed additives, other pharmaceutical products, and other non-pharmaceutical products. Its Consumer Healthcare segment provides non-prescription products in therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Louise Chen Guggenheim Securities LLC Buy   Sep 13, '18     45.00  Sep 13, '19  N/A 
Alex Arfaei BMO Capital Markets Buy   Sep 05, '18       Sep 05, '19  N/A 
Brandon Couillard Jefferies & Co. Buy   Aug 28, '18     74.00  Aug 28, '19  N/A 
David Risinger Morgan Stanley Buy   Aug 23, '18     45.00  Aug 23, '19  N/A 
Gregg Gilbert BofA Merrill Lynch Buy   Aug 21, '18     45.00  Aug 21, '19  N/A 
Alex Arfaei BMO Capital Markets Buy   Jul 31, '18     42.00  Jul 31, '19  N/A 
Louise Chen Guggenheim Securities LLC Buy   Jul 31, '18     45.00  Jul 31, '19  N/A 
Alex Arfaei BMO Capital Markets Buy   Jun 25, '18     42.00  Jun 25, '19  N/A 
Louise Chen Guggenheim Securities LLC Buy   Jun 07, '18     45.00  Jun 07, '19  N/A 
Andrew Baum Citi Sell   Apr 12, '18       Apr 12, '19  N/A 
Alex Arfaei BMO Capital Markets Buy   Mar 06, '18     43.00  Mar 06, '19  N/A 
David Risinger Morgan Stanley Buy   Jan 31, '18     43.00  Jan 31, '19  N/A 
Geoff Meacham JPMorgan Buy   Jan 30, '18     41.00  Jan 30, '19  N/A 
Jason Gerberry Leerink Swann Llc Buy   Jan 30, '18     40.00  Jan 30, '19  N/A 
Alex Arfaei BMO Capital Markets Buy   Jan 25, '18     39.00  Jan 25, '19  N/A 
Alex Arfaei BMO Capital Markets Buy   Dec 15, '17     39.00  Dec 15, '18  N/A 
Alex Arfaei BMO Capital Markets Buy   Nov 10, '17     39.00  Nov 10, '18  N/A 
Marc Goodman UBS Buy   Nov 01, '17     38.00  Nov 01, '18  N/A 
Richard Purkiss Atlantic Equities Buy   Oct 31, '17     54.00  Oct 31, '18  N/A 
Gregg Gilbert BofA Merrill Lynch Buy   Oct 11, '17     38.00  Oct 11, '18  N/A 
< previous123456